Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated potassium channels Kv3.2 (KCNC2) and Kv3.4 (KCNC4) are members of the Shaw-related subfamily, distinguished by their high activation thresholds and ultra-fast gating kinetics. These unique biophysical properties allow them to mediate rapid repolarization of action potentials, which is essential for the high-frequency firing (fast-spiking) phenotype of specific neuronal populations, such as parvalbumin-positive GABAergic interneurons in the cortex and hippocampus. Kv3.2 is primarily localized in the central nervous system and plays a critical role in maintaining the balance between excitation and inhibition; its dysfunction is linked to schizophrenia, epilepsy, and hearing disorders. Kv3.4 is expressed in both the brain and peripheral sensory neurons, such as dorsal root ganglion (DRG) cells, where it regulates nociceptive signaling and has been implicated in the pathogenesis of Alzheimer's and Parkinson's diseases. Therapeutic development focuses on positive allosteric modulators (PAMs), such as the AUT series of compounds, which aim to restore neuronal firing patterns in neuropsychiatric conditions. Conversely, Kv3.4 inhibition is explored as a strategy for managing chronic pain and neurodegeneration.
Positive allosteric modulation (PAM) of Kv3.1/3.2 channels; Voltage-gated channel blocking; Gating modification
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 2 and member 4 (Kv3.2 and Kv3.4).